Oral Film for Acute Migraine Treatment Closer to FDA Approval
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraine," RedHill Biopharma, http://www.redhillbio.com/wp-content/uploads/2014/02/RedHill-Biopharma-and-IntelGenx-Receive-Complete-Response-Letter-from-FDA-for-RHB-103-Oral-Film-for-Acute-Migraines.pdf, accessed February 6, 2014.
- "RedHill Biopharma Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine PDUFA Goal Date of February 3, 2014," RedHill Biopharma, http://www.redhillbio.com/wp-content/uploads/2013/06/RedHill-Announces-FDA-Acceptance-for-Review-of-RHB-103-Migraine-NDA-and-PDUFA-Date.pdf, accessed February 6, 2014.
- Merriam-Webster Dictionary, "Bioequivalence," http://www.merriam-webster.com/dictionary/bioequivalence, accessed February 6, 2014.
- Merriam-Webster Dictionary, "Bioavailability," http://www.merriam-webster.com/dictionary/bioavailability, accessed February 6, 2014.